This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
5/10/2022
Conference Operator
Moderator
Mari Raycroft at Jefferies. Dr. Raycroft, your line is open.
Mari Raycroft
Analyst, Jefferies
Hi, good morning. Congrats on the progress and thanks for taking my questions. Let's see, so just wondering if you can elaborate on patient discontinuations that you mentioned in your 4Q update. Are these transient compliance issues or related to how the doctor is managing the patient or are there any other insights or explanations you can provide at this point?
Peter [Last Name Unknown]
Company Executive (CEO/President)
Yeah, I'm going to ask Max to join me on that conversation. I think my answer would be it's across the board. And we're providing six months of data because we have a healthy number of patients who have crossed six months of therapy. Obviously, since we launched at the end of January, the number of patients seeing 12 months of therapy is lighter. So, as we go forward, we'll start to give longer-term views on that. But, Max, you want to give any color as to, you know, why patients, you know, the 30% or so might be falling off the product? Yes, sure.
You're reading a preview of the AUPH Q1 2022 earnings call.
Free account.
Disclaimer